Literature DB >> 7593900

Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%).

A C Degrémont1, M Ismaïl, M Arthaud, B Oulare, O Mundler, M Paris, J F Baron.   

Abstract

OBJECTIVE: To define the mechanisms of the stable and prolonged post-operative plasma volume expansion observed with Hydroxyethyl Starches (HES) and to determine whether a partial intravascular hydrolysis of large molecules contribute to reinforce the colloid-osmotic effect.
DESIGN: Prospective, pharmacologic study using single dose of drug.
SETTING: University-based, post-anesthesia care unit. PATIENTS: The protocol was performed during the post-operative period, in 10 patients after stable recovery from general anesthesia for carotid endarterectomy.
INTERVENTIONS: HES 200/0.62 (500 ml) was infused over 30 min. Standard hemodynamic and biological variables, HES concentration and colloid osmotic pressure were obtained at each measurement. Plasma volume was calculated using 51Cr-labelled RBCs. Patterns of changes in number average molecular weight (MWn) and weight average MW (MWw) were measured using gel permeation chromatography. Measurements were obtained at control, end of infusion, 1 h, 3 h, 6 h and 24 h after infusion.
MEASUREMENTS AND MAIN RESULTS: Plasma volume increased by 693 ml (+21%) after the infusion of HES and remained constant over 24 h. HES concentration progressively decreased to reach a value of 35% of the peak at 24 h. MWn and MWw, initially decreased when compared with the dose solution and changed little in the 24 h study period. Diuresis significantly decreased at 3 h up to 24 h. Plasma albumin decreased after infusion and then progressively increased to reach a significantly higher value at 24 h than after infusion.
CONCLUSION: Initial plasma volume expansion and decrease in HES concentration agree with previously-published data. Maintenance of plasma volume expansion over 24 h was not related to a partial intravascular hydrolysis. Low elimination rate of HES, extravascular mobilization of albumin and post-operative renal adaptations were possibly the 3 main mechanisms to explain a prolonged plasma volume expansion with HES 200/0.62, 6%.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593900     DOI: 10.1007/BF01700163

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  34 in total

1.  Intracranial bleeding during treatment with hydroxyethyl starch.

Authors:  L Damon; M Adams; R B Stricker; C Ries
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

2.  Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion.

Authors:  E C Rackow; C Mecher; M E Astiz; M Griffel; J L Falk; M H Weil
Journal:  Crit Care Med       Date:  1989-05       Impact factor: 7.598

Review 3.  Hetastarch: an overview of the colloid and its metabolism.

Authors:  J D Hulse; A Yacobi
Journal:  Drug Intell Clin Pharm       Date:  1983-05

4.  [The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine (author's transl)].

Authors:  H Köhler; H Zschiedrich; A Linfante; F Appel; H Pitz; R Clasen
Journal:  Klin Wochenschr       Date:  1982-03

5.  Fluid volume and albumin kinetics occurring with major surgery.

Authors:  R C Hoye; S H Bennett; G W Geelhoed; C Gorschboth
Journal:  JAMA       Date:  1972-12-04       Impact factor: 56.272

6.  Studies on hydroxyethyl starch. Part II: Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers.

Authors:  H P Ferber; E Nitsch; H Förster
Journal:  Arzneimittelforschung       Date:  1985

7.  Low molecular weight hydroxyethyl starch 6% compared to albumin 4% during intentional hemodilution.

Authors:  J F Baron; D De Kegel; A C Prost; O Mundler; M Arthaud; G Basset; G Maistre; F Masson; A Carayon; C Landault
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

8.  Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock.

Authors:  E C Rackow; J L Falk; I A Fein; J S Siegel; M I Packman; M T Haupt; B S Kaufman; D Putnam
Journal:  Crit Care Med       Date:  1983-11       Impact factor: 7.598

9.  Albumin abuse in intensive care medicine.

Authors:  A F Grootendorst; M G van Wilgenburg; P H de Laat; B van der Hoven
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

10.  Biliary excretion of hydroxyethyl starch in man.

Authors:  T F Kalhorn; A Yacobi; C Y Sum
Journal:  Biomed Mass Spectrom       Date:  1984-04
View more
  5 in total

1.  Volume expansion of albumin, gelatin, hydroxyethyl starch, saline and erythrocytes after haemorrhage in the rat.

Authors:  Johan Persson; Per-Olof Grände
Journal:  Intensive Care Med       Date:  2004-12-18       Impact factor: 17.440

Review 2.  [Hemodilution and infusion therapy for hypovolemic shock. Clinical physiological and pharmacological aspects].

Authors:  H A Adams
Journal:  Anaesthesist       Date:  2007-04       Impact factor: 1.041

3.  Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers.

Authors:  J Waitzinger; F Bepperling; G Pabst; J Opitz; M Müller; J François Baron
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

4.  [Exact measurement of the volume effect of 6% hydoxyethyl starch 130/0.4 (Voluven) during acute preoperative normovolemic hemodilution].

Authors:  M Jacob; M Rehm; V Orth; M Lötsch; H Brechtelsbauer; E Weninger; U Finsterer
Journal:  Anaesthesist       Date:  2003-10       Impact factor: 1.041

5.  Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer; Luigi U Gaioni; Francesco Zaraca; Michael Joannidis
Journal:  Crit Care       Date:  2010-10-28       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.